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  Abstract 
 
Objective: The objective of this selective EBM review is to determine “Is Vitamin D 
supplementation effective at reducing idiopathic musculoskeletal (MSS) pain?”  
 
Study Design: Review of primary studies published between the years 2012-2014.  
 
Data Sources: One double blind randomized controlled trial (RCT), one semi-crossover RCT, 
and one before and after observational study. These were found using Cochrane Review and 
PubMed databases. 
 
Outcomes Measured: Clinical outcomes were measured in these studies utilizing the Visual 
Analogue Scale for Pain, the 5-point Likert Pain Scale, the Standard Nordic Questionnaires and 
numerical grading of pain level, and number of pain sites before and after Vitamin D3 
supplementation.  
 
Results: In a RCT by Knutsen et. al (2014), pain scores were improved in the experimental group 
receiving supplementation with Vitamin D3 as compared to placebo, but results were not 
significant. The double-blind, semi-crossover RCT by Schreuder et. al (2012) found significant 
improvement in nonspecific MSS pain after 6 weeks of Vitamin D3 supplementation and mixed 
results after 12 weeks of supplementation. The before and after observational study performed by 
Le Goaziou et. al (2014) also found significantly decreased pain sensation in participants after 
Vitamin D3 supplementation as compared to baseline.  
 
Conclusions: There is conflicting data in regard to the relationship between Vitamin D stores and 
MSS pain. To determine whether or not Vitamin D3 supplementation significantly improves 
idiopathic MSS pain, there needs to be more double-blind randomized controlled trials 
performed for analysis.  
 
Keywords: Vitamin D, musculoskeletal pain 
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INTRODUCTION 
 
Pain is the most common complaint that health care providers treat.1 Chronic pain is 
characterized as painful symptoms lasting for at least a three month duration.2 Pain of 
musculoskeletal origin can be the result of underlying disease processes such as inflammatory or 
autoimmune conditions, infections, neoplasms, renal deficiency, hyperlipidemia, advanced age, 
pharmacotherapeutic reactions, or idiopathic in origin.1 Whether there is a link between Vitamin 
D deficiency and idiopathic musculoskeletal pain is controversial. This paper evaluates three 
clinical trials that considered the efficacy of Vitamin D3 supplementation for improving 
nonspecific, idiopathic musculoskeletal pain. 
More than 20% of outpatient visits are based on musculoskeletal complaints (both 
chronic and acute), comprising more than 315 million outpatient visits annually.1 The average 
healthcare expenditure on chronic pain management in the US is $125 billion, with low back 
pain alone costing around $86 billion.2 Vitamin D deficiency, defined as 25(OH)D serum levels 
less than 20 ng/mL, affects 29% of post-menopausal women and 25% of men over the age of 65 
years old in the U.S.3  Recent interest in the potential sequelae of Vitamin D deficiency, 
including musculoskeletal pain, has prompted over-the-counter Vitamin D supplementation 
purchases to rise nearly 10-fold throughout the early 2000’s.4  
It has been proposed that chronic pain is influenced by three key factors: an incurable 
disease, unresolved neural factors from a previous disease, or psychological conditions such as 
anxiety or depression.2,5 However, these explanations do not account for the etiology or 
pathophysiology of idiopathic musculoskeletal pain. It is known that the sensation of pain itself is 
due to neuropathic processes originating in the body’s nociceptive sensory stimuli.5 These 
communicate via the thalamus, brainstem and somatosensory cortex to evoke an emotional 
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response regulated by both the limbic system and neurotransmitters such as serotonin and 
norepinephrine.5 Vitamin D might indirectly have an effect on this pain perception since it 
enhances bone mineral composition by increasing the body’s absorption of calcium and 
phosphorus.3 Theoretically, this could have a profound impact on musculoskeletal symptoms as 
hypocalcemia predisposes individuals to rickets and osteomalacia while hypophosphatemia can 
induce muscle weakness, bone pain and decreased bone integrity.3,6 In support of this theory, a 
higher frequency of musculoskeletal pain has been reported among Vitamin D deficient 
individuals indigenous to areas with low sunlight exposure.7 Furthermore, Vitamin D receptors 
are found in most cells and tissues throughout the body, including muscle cells and immune 
cells, reinforcing its potential influence on idiopathic musculoskeletal pain.3 	  
Since idiopathic musculoskeletal pain has unknown causation, the current standard 
approach to treatment is multidisciplinary and palliative. This includes NSAIDs and 
acetaminophen for mild to moderate symptom relief along with heat and cryotherapy.3 
Modalities such as physical therapy and acupuncture can be beneficial as well.3 Long-acting 
opioids, such as morphine and oxycodone, are implemented with caution for debilitating pain 
unresponsive to aforementioned approaches.2 Because chronic musculoskeletal pain can be a 
psychosomatic manifestation of an underlying psychiatric disorder, a trial of cognitive behavioral 
therapy or tricyclic antidepressants can sometimes reveal an undiagnosed mood disorder and 
provide relief.2 The pathophysiology of Vitamin D suggests a potentially promising and 
affordable treatment alternative for joint and muscle pain with a favorable risk-benefit ratio.  
OBJECTIVE 
The objective of this selective EBM review is to determine “Is Vitamin D 
supplementation effective at reducing idiopathic musculoskeletal (MSS) pain?” 
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METHODS 
This investigation looks at two double-blind randomized controlled trials, including one 
semi-crossover study, and one observational before and after study. Each study included both 
male and female Vitamin D deficient participants with similar demographic parameters amongst 
experimental and placebo groups in the controlled trials.7,8,9 Knutsen et. al utilized one 
experimental group combined of participants receiving 10µg or 25µg of Vitamin D3 as compared 
to a control group receiving a visibly matched placebo.7 The semi-crossover controlled trial by 
Schreuder et. al gave one experimental group a single 150,000 IU dose at baseline and again at 6 
weeks, the second experimental group a 150,000 IU dose of Vitamin D3 at baseline followed by 
a visually matched placebo at 6 weeks, and the third group received a placebo at baseline 
followed by a single 150,000 IU dose of Vitamin D3 at 6 weeks.8 Outcomes at 6 weeks and 12 
weeks were measured.8 Participants in the before and after observational study received between 
400,000 to 600,000 IU of Vitamin D3 dependent upon individual baseline serum Vitamin D 
levels.9 All studies examined patient oriented outcomes by evaluating changes in MSS pain from 
baseline in response to improved Vitamin D deficiency.7,8,9 
This systematic review included searches in the Cochrane Review and PubMed 
databases. The two randomized controlled trials were published in peer reviewed English 
journals between the years of 2012 to 2014. Le Goaziou et. al published their work in French the 
2014 Edition of the European Journal of General Practice, which was then translated into 
English. Key words utilized to find these articles were “Vitamin D” and “musculoskeletal pain.” 
Each study utilized similar inclusion and exclusion criteria with more stringent exclusion 
parameters in the two controlled trials as demonstrated by Table 1. The inclusion criteria 
included adults aged 18 to 60 years-old with chronic MSS pain of unknown origin who had been 
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diagnosed with Vitamin D deficiency. This review attempted to exclude studies with participants 
who had comorbidities that could interfere with Vitamin D metabolism. The inclusion and 
exclusion criteria for each study is outlined below (see Table 1).    
Table 1: Demographics & Characteristics of Included Studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion Criteria Exclusion 
Criteria 
W/D Interventions 
Schreuder 
(2012) 
Semi-
crossover 
randomized 
controlled 
trial 
 
84 18-
60 
years 
old 
- > 1 parent born 
in a non-Western   
country.  
Vitamin D <50 
nmol/L.  
> 3 nonspecific 
MSS pain 
episodes of >1 
month duration 
in 2 years, or 
ongoing for 3 
months, without 
obvious cause 
 
Pregnancy, 
Rickets, 
Sarcoidosis or 
Tuberculosis. 
Use of statins,  
cyclosporines or 
oral steroids. 
Use of Vitamin 
D in last 4 mo’s.  
Ca > 2.55 
mmol/L. 
Cr > 150  
mmol/L 
ESR > 30 mm/h. 
 
 
5 lost 
to f/u 
in the 
first 6 
wks. 
 
10 lost 
to f/u 
in the 
second 
6 wks. 
 
 
1 dose of  
Vitamin D3 
150,000 IU 
verses 
placebo. 
Evaluated at  
6 wks and 
again at 12 
wks 
Knutsen 
(2014) 
 
Double-
blind 
randomized 
controlled 
trial 
 
251 
 
18-
50 
years 
old 
Assumed healthy 
population 
experiencing 
MSS pain. 
Vitamin D <50 
nmol/L.  
Born in or 
children of 
parents born in 
the Middle East, 
Africa or South 
Asia. 
-  
Same as above 
except no 
exclusion of 
statins or 
cyclosporines and 
no lab testing 
parameters.  
Plus exclusion of 
breastfeeding, 
CA, renal 
disease, 
osteoporosis, 
recent fracture 
and the use of 
pain killers, 
thiazides, 
epileptics or HRT 
36 Vitamin D3, 
10 µg or 25 
µg PO qd x 16 
weeks  
 
Le Goaziou 
(2014)  
Before and 
after 
observationa
l study 
69 18-
50 
years 
old 
Diffuse MSS 
pain. 
Vitamin D <50  
nmol/L. 
Identified 
causation of MSS 
pain 
 
20 1 dose of 400- 
600,000 IU 
Vitamin D3. 
Examined 45-
60 days later. 
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Schreuder et. al outlined parameters to specify chronicity of pain, classified as at least 3 
episodes of 1 month duration of pain for 2 years or continuous pain for 3 months, whereas 
Knutsen et. al and Le Goaziou et. al selected participants who sought consultation from their 
general practitioner for MSS pain.7,8,9 Exclusion criteria included in both randomized controlled 
trials were pregnancy, renal disease, tuberculosis, sarcoidosis or osteoporosis, and use of Vitamin 
D supplements or medications that interfere with Vitamin D metabolism. Exclusion criteria 
specific to Schreuder et. al included signs of rickets, ESR > 30 mm/h, serum calcium > 2.55 
mmol/L, and serum creatinine > 150 mmol/L.8 Exclusion criteria specific to the study by 
Knutsen et. al included use of strong pain medication, breastfeeding or a recent fracture.7 Le 
Goaziou et. al did not disclose exclusion criteria for the observational study, however phototype, 
body mass index, use of body-covering clothes, diet, sun exposure, pain, fatigue, impact of pain 
on quality of life and health insurance coverage were considered and matched to the best 
capacity when selecting study participants.9  
 Statistical analysis in all three studies utilized p values to determine the significance of 
mean changes in pain from baseline. Only Schreuder et. al reported dichotomous data, which 
allowed for calculation of the control event rate (CER), experimental event rate (EER), relative 
benefit increase (RBI), and absolute benefit increase (ABI). The numbers needed to treat (NNT) 
was then determined from the ABI, while numbers needed to harm (NNH) was not applicable 
due to absence of significant adverse participant outcomes.8 This study utilized the Pearson X2 
test to determine an association between VAS reports and Likert Scale scores, which allowed for 
imputation of missing Likert scales for four participants who were lost to follow up.8 Knutsen et. 
al reported the odds ratio (OR) and confidence interval (CI) of the study’s results and utilized the 
Generalized Estimating Equation Poisson Regression Model to adjust outcome variables and 
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account for the likelihood that reported pain levels were influenced by participants’ number of 
pain sites.7 Le Goaziou et. al utilized a Chi-Square Test for baseline data to determine post-
intervention comparison.9 The evolution of mean pain scores was then determined with mixed 
model analysis and adjusted for BMI, age and gender.9 
OUTCOMES MEASURED 
All three studies examined the efficacy of Vitamin D3 supplementation to decrease MSS 
pain levels in individuals with Vitamin D deficiency. Knutsen et. al examined its effects on pain 
parameters as demonstrated by changes in reported MSS pain, utilizing the Standard Nordic 
Questionnaire, after 16 weeks of supplementation.7 Schreuder et. al had participants record pain 
results on the following 5-point Likert Scale: Much Less Pain, Less Pain, Equal Pain, More Pain, 
or Much More Pain. This was measured at 6 weeks and again at 12 weeks into the study.8 The 
location and intensity of pain was also measured with VAS questionnaires, scaled from 0-100 (0 
translating as “no pain” and 100 translating as “worst imaginable pain), with consideration of 
four key pain sites (shoulder, low back, arms and legs and joints).8 Le Goaziou et. al measured a 
mean pain evaluation score with a questionnaire that specified the location of pain, duration of 
pain, intensity of pain, and the use of analgesics.9  
RESULTS 
All three of these studies yielded different results about the effects of Vitamin D3 
supplementation on MSS pain. The Likert scale pain scores collected by Schreuder et. al yielded 
statistically significant decreases in pain levels, with 34.9% improvement in the Vitamin D3 
group of 44 participants compared to 19.5% improvement in the placebo group of 40 participants 
(P=0.04), yielding 7 numbers needed to treat (see Table 2).8  These values were calculated with 
imputation for missing data (however, calculations without imputation also yielded statistically 
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significant improvement).8 At 12 weeks, the only statistically significant difference in pain relief 
on Likert Scales was seen between the group of 24 participants that received Vitamin D3 for both 
interventions, with a 61.9% improvement rate, verses the arm comprised of 33 participants that 
received placebo for the first 6 weeks then Vitamin D3 for the second 6 weeks, with a 12.6% 
improvement rate (P=0.005). This difference yielded 3 numbers needed to treat (see Table 2).8  
The difference in pain scales between Vitamin D-Vitamin D vs. Vitamin D-Placebo groups as 
well as the Vitamin D-Placebo and Placebo-Vitamin D groups in this semi-crossover clinical 
trial yielded no statistically significant results, with p-values > 0.05 in both instances.8 This data 
is based on a total of 79 participants during the first 6 week analysis (after losing 5 participants to 
follow up) and 69 participants in the second analysis at 12 weeks, resulting in an 18% total loss 
to follow-up in this study.8  
Table 2: Calculations for treatment from Schreuder et. al8 
Intervention Treatment Interval CER EER RBI ABI NNT 
  Vitamin D vs. Placebo 6 weeks 19.5% 34.9% 78.97% 15.4% 7 
Vitamin D-Vitamin D 
vs. Placebo-Vitamin D 
12 weeks 12.6% 61.9% 391% 49.3% 3 
 
The observational study by Le Goaziou et. al also found a statistically significant 
difference between baseline and post-intervention results. Mean pain values at baseline were 5.1 
and decreased to 2.8 when measured at follow up after their single dose of Vitamin D3 
intervention (P<0.001).9 (See Figure 1) The scaling for reported data was not specified. There 
were initially 69 participants in this study with a 29% loss to follow-up, resulting in a total of 49 
participants.9 
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Figure 1: Before and After Study Results for Vitamin D3 Supplementation by Le Goaziou et. al  
 
The RCT by Knutsen et. al did not demonstrate statistically significant changes in pain 
level with Vitamin D3 supplementation. The Vitamin D group reported a 20% decrease in pain, 
similar to the control group that reported an 18% decrease in pain (P=0.82).7 The confidence 
interval (CI) of these reported results was large (0.34-3.96) and the odds ratio (OR) was 1.15 
once values were adjusted for age, gender and baseline Vitamin D3 level, indicating that the 
intervention was not effective (See Figure 2).7 The study began with 251 eligible participants, 
and concluded with 215 participants, resulting in an approximate 15% loss to follow-up.7 Out of 
those participants, 180 individuals returned their Vitamin D3 tablet boxes as requested for 
compliance analysis.7 80% of the cohort had consumed 80% of the allotted tablets while 69% 
had consumed 90% of the tablets.7 
 
Figure 2: Results for Vitamin D3 Supplementation by Knutsen et. al 
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All three studies reported minimal to no adverse effects that were unrelated to the 
intervention.7,8,9 Knutsen et. al reported that 21 of their participants experienced new onset of 
symptoms.7 However, these were distributed equally amongst placebo and control groups and 
not attributable experimental supplementation.7 Vitamin D3 is a naturally metabolized substance 
and all participants were deficient in the nutrient. It takes chronic ingestion of more than 40,000-
100,000 IU per day to reach Vitamin D3 toxicity, so this was not of concern.7,10  
DISCUSSION 
 Vitamin D3 has received public attention in recent years for its potential link to chronic 
conditions such as unexplained depression, MSS pain, cancers, cardiovascular disease and 
metabolic disorders.3 The potential efficacy of this nutrient is valuable because patients who seek 
care for idiopathic MSS pain have few safe and affordable long-term treatment options. 
Palliative modalities such as physical therapy, massage and acupuncture relief often do not 
qualify for insurance coverage. Chronic NSAID use can result in gastric bleeding or ulceration, 
while chronic ASA use can induce hepatotoxicity.2 Opioids impose risk of dependency and have 
potent ADR’s that interfere with activities of daily living, most notably chronic constipation, 
cognitive impairment and dependence.2 Vitamin D3 is a safe and affordable over-the-counter 
alternative that is naturally metabolized by the hepatic and renal systems without proven adverse 
effects when utilized at the recommended daily doses.3,7-9  
Although two of the included studies demonstrated some improvement in MSS pain with 
Vitamin D3 supplementation, limitations in these studies challenge the efficacy of reported 
results. One key outlier was the inconsistency in regulation of pain relieving medications among 
participants. Schreuder et. al attempted to standardize this variable by allowing participants to 
use pain relieving medications and record their usage, which was similar across groups, and 
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Knutsen et. al measured pain medication uses as an outcome variable.7,8 However, analgesic 
effects on pain perception could have a profound impact on reported pain scales. Furthermore, 
although researchers attempted to match baseline pain levels amongst participants, 
individualized pain thresholds make it difficult to draw objective conclusions from study results.  
There were other limitations that may have affected the outcome of these studies such as 
the relatively short duration of each trial. For instance, some participants in the study by Knutsen 
et. al did not surpass the level of Vitamin D deficiency by trial’s conclusion.7 This suggests that a 
longer duration of supplementation might potentially lead to more pronounced and significant 
improvements. The RCT by Knutsen et. al also relied on participants to comply with daily doses 
of Vitamin D3 supplements, which resulted in altered outcomes from a degree of noncompliance 
as reported by the study (see Results section). Furthermore, the participant selection criteria for 
these studies did not account for all of conditions that could affect chronic pain as well as the 
metabolism of Vitamin D. Of particular concern, these trials did not disclose if screening for 
psychological conditions was performed. Since mental health conditions can manifest 
psychosomatically as pain, participants in these studies may have had underlying conditions 
influencing their pain perception that cannot be treated by vitamin supplementation.7-9 
Additionally, only Schreuder et. al excluded participants who had excess serum concentration of 
minerals that could influence Vitamin D metabolism and MSS pain. Meanwhile, Knutsen et. al 
simply excluded a handful of the many conditions that influence these factors and Le Goaziou et. 
al neglected to outline specific exclusion criteria.7,8 Without stringent inclusion and exclusion 
criteria, the efficacy of interventions in these studies is questionable.  
Validity was an issue in all three studies. The study by Le Goaziou et. al had the most 
profound improvement in pain, however it was the least valid study. This research could not 
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establish a causal effect from the intervention due to the fact that it was an observational study 
that did not keep participants or researchers blind to the intervention.9 Furthermore, the study had 
loss to follow-up rates exceeding 20%.9 Knutsen et. al did implement a more reliable randomized 
controlled trial to measure data, however researchers combined the two experimental arms 
receiving 10µg and 25µg of Vitamin D3 daily and compared these groups as a whole to the 
control.7 It is questionable why the researchers chose this approach, and the grouping of two 
differently dosed interventions decreases the validity of the results.7 While Schreuder et. al did 
find improvement in pain reports via the Likert Scale, there was conflicting data amongst the 
three study arms.8 The reason for this is unclear, but the inconsistency decreases the likelihood of 
reproducible results.  
CONCLUSION 
 Despite its potential appeal, existing data is inconclusive in determining whether or not 
Vitamin D3 is an effective means of alleviating idiopathic musculoskeletal pain. Although these 
studies attempted to account for a number of potential outliers, it is difficult to guarantee validity 
in studies that rely on patient oriented outcomes such as pain scale due to its subjectivity. In 
order to control for these factors, future studies designed as double-blind randomized controlled 
trials need to be taken underway. Future studies should be longer in duration, should have 
extensive screening protocols for pain-inducing comorbidities, and should implement ongoing 
extraneous analgesic control. Until more reliable studies are complete, it cannot be confirmed 
whether supplementation with Vitamin D3 can improve idiopathic MSS pain in individuals who 
are Vitamin D deficient. 
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